Haemaccel

Haemaccel (a registered trademark) is a type of intravenous colloid used in the prevention or treatment of shock associated with reduction in effective circulating blood volume due to hemorrhage, loss of plasma (burns, peritonitis, pancreatitis, crush injuries), or loss of water and electrolytes from persistent vomiting and diarrhea. Haemaccel contains degraded gelatin.

Haemaccel (also marketed as Emagel in Italy and Solucel in Venezuela) was originally brought to market by Sanofi-Aventis, and later acquired by Piramal Enterprises.

It can be used as an alternative treatment for a Jehovah's Witness patient who refuses a blood transfusion.